StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
51
This month
2
This week
1
This year
3
Yesterday
1
Publishing Date
2024 - 04 - 23
1
2024 - 04 - 19
1
2024 - 02 - 12
1
2023 - 12 - 21
1
2023 - 12 - 20
1
2023 - 11 - 21
1
2023 - 11 - 01
1
2023 - 10 - 27
1
2023 - 10 - 25
1
2023 - 10 - 18
1
2023 - 09 - 20
1
2023 - 09 - 11
1
2023 - 07 - 20
1
2023 - 06 - 19
1
2023 - 05 - 26
1
2023 - 05 - 25
1
2023 - 05 - 10
1
2023 - 04 - 27
1
2023 - 04 - 04
1
2023 - 03 - 31
1
2023 - 02 - 16
1
2023 - 01 - 19
1
2023 - 01 - 13
1
2022 - 11 - 11
2
2022 - 11 - 10
1
2022 - 09 - 16
1
2022 - 09 - 06
1
2022 - 09 - 02
1
2022 - 07 - 29
1
2022 - 07 - 21
1
2022 - 07 - 20
1
2022 - 07 - 13
1
2022 - 06 - 24
1
2022 - 06 - 02
1
2022 - 05 - 03
1
2022 - 04 - 12
1
2022 - 02 - 28
1
2022 - 01 - 31
1
2021 - 12 - 21
1
2021 - 11 - 12
1
2021 - 09 - 15
1
2021 - 08 - 25
1
2021 - 07 - 29
1
2021 - 05 - 21
1
2021 - 04 - 28
1
2021 - 04 - 14
1
2021 - 03 - 29
1
2021 - 03 - 24
1
2021 - 03 - 12
1
2021 - 03 - 03
1
Sector
Health technology
51
Manufacturing
7
N/a
1
Producer manufacturing
1
Tags
Alliances
16
Antibody
7
Application
11
Approval
21
Asia
15
Biotech
6
Biotech-bay
10
Biotech-beach
18
Cabometyx
7
Cancer
35
Cell carcinoma
7
Children
7
Clinical-trials-phase-ii
10
Clinical-trials-phase-iii
23
Collaboration
15
Covid
11
Covid-19
10
Disease
33
Drug
30
Earnings
23
Events
8
Expected
7
Fda
17
Financial
17
Financial results
13
Gene therapies
6
Gene therapy
6
Genetown
22
Global
51
Growth
29
Hereditary angioedema
8
Injection
6
Japan
7
License
13
Liver
16
Market
85
Money
11
N/a
187
Nivolumab
6
Partnership
6
People
7
Pharmaceutical
17
Phase 2
6
Phase 3
19
Positive
15
Product-news
10
Rare
11
Reach
12
Renal
7
Report
46
Research
41
Results
58
Sars-cov-2
6
Study
8
Takhzyro
7
Therapeutics
37
Therapy
43
Treatment
51
Trial
36
Vaccine
27
Entities
Abbott laboratories
3
Abbvie inc.
5
Adc therapeutics sa
1
Albireo pharma, inc.
1
Amgen inc.
2
Amicus therapeutics, inc.
1
Arrival
1
Arrowhead pharmaceuticals, inc.
3
Astellas pharma inc
4
Astrazeneca plc
1
Bausch health companies inc.
3
Bio-techne corp
1
Biomarin pharmaceutical inc.
1
Bristol-myers squibb company
8
Eli lilly and company
10
Exelixis, inc.
3
Genmab a/s
1
Gilead sciences, inc.
2
Glaxosmithkline plc
3
Hoth therapeutics, inc.
1
Hutchison china meditech limited
3
Immunogen, inc.
1
Ironwood pharmaceuticals, inc.
1
Jazz pharmaceuticals plc
1
Johnson & johnson
11
Karyopharm therapeutics inc.
1
Longeveron llc - class a
1
Mallinckrodt plc
1
Mirum pharmaceuticals, inc.
1
Novartis ag
12
Novo nordisk a/s
2
Ovid therapeutics inc.
1
Pfizer, inc.
4
Processa pharmaceuticals, inc.
1
Rallybio corp
1
Sanofi
11
Spectrum pharmaceuticals, inc.
1
Stryker corporation
1
Sutro biopharma, inc.
1
Takeda pharmaceutical co ltd
1
Takeda pharmaceutical company limited
51
Teva pharmaceutical industries ltd
3
Ucb s.a.
1
Viatris inc.
2
Zymeworks inc.
1
Symbols
ABBV
117
ABT
57
ADMP
19
ALNY
38
ALPMF
51
ALPMY
51
AMGN
46
ARQT
24
ARWR
22
AZN
46
AZNCF
38
BHC
35
BIIB
41
BMY
93
BSX
21
BTAI
19
BWAY
39
CHRS
28
CNSP
26
ECL
47
FBIO
27
FNCTF
84
GILD
50
GLAXF
73
GSK
98
HOTH
24
HZNP
19
INCY
77
IONS
19
JNJ
198
KPTI
27
LLY
175
MBRX
28
MDT
44
MMM
20
MNOV
24
MRK
63
NRXP
19
NTLA
31
NVO
34
NVS
138
NVSEF
114
PFE
74
PHG
20
PRGO
19
RARE
25
REGN
58
RETA
28
RGNX
25
SNY
281
SNYNF
233
SRNE
37
TAK
51
TEVJF
76
TGTX
24
TNXP
29
VRCA
23
VRTX
27
VTRS
45
XYL
35
Exchanges
Nasdaq
34
Nyse
51
Crawled Date
2024 - 04 - 24
1
2024 - 04 - 19
1
2024 - 02 - 12
1
2023 - 12 - 22
1
2023 - 12 - 20
1
2023 - 11 - 21
1
2023 - 11 - 01
1
2023 - 10 - 27
1
2023 - 10 - 25
1
2023 - 10 - 18
1
2023 - 09 - 20
1
2023 - 09 - 11
1
2023 - 07 - 20
1
2023 - 06 - 19
1
2023 - 05 - 27
1
2023 - 05 - 25
1
2023 - 05 - 10
1
2023 - 04 - 28
1
2023 - 04 - 04
1
2023 - 03 - 31
1
2023 - 02 - 16
1
2023 - 01 - 19
1
2023 - 01 - 13
1
2022 - 11 - 11
2
2022 - 11 - 10
1
2022 - 09 - 16
1
2022 - 09 - 06
1
2022 - 09 - 02
1
2022 - 07 - 29
1
2022 - 07 - 21
1
2022 - 07 - 20
1
2022 - 07 - 13
1
2022 - 06 - 24
1
2022 - 06 - 02
1
2022 - 05 - 03
1
2022 - 04 - 12
1
2022 - 02 - 28
1
2022 - 01 - 31
1
2021 - 12 - 21
1
2021 - 11 - 12
1
2021 - 09 - 15
1
2021 - 08 - 25
1
2021 - 07 - 29
1
2021 - 05 - 21
1
2021 - 04 - 28
1
2021 - 04 - 15
1
2021 - 03 - 29
1
2021 - 03 - 24
1
2021 - 03 - 12
1
2021 - 03 - 04
1
Crawled Time
00:00
5
00:20
1
01:00
2
02:00
2
08:00
2
09:00
1
10:00
3
10:48
1
11:00
2
12:00
2
13:00
8
14:00
4
15:00
1
15:20
1
17:00
3
18:00
5
19:00
1
20:00
1
21:00
2
22:00
3
23:00
1
Source
investors.ovidrx.com
1
www.biospace.com
22
www.globenewswire.com
3
www.prnewswire.com
25
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Treatment
symbols :
Tak
save search
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published:
2024-04-23
(Crawled : 00:00)
- prnewswire.com
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
0.0%
|
O:
-1.05%
H:
0.85%
C:
0.85%
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
0.0%
|
O:
-0.71%
H:
0.0%
C:
0.0%
granted
approval
cancer
treatment
for
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published:
2024-04-19
(Crawled : 02:00)
- prnewswire.com
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
1.48%
|
O:
0.42%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
3.41%
|
O:
0.82%
H:
0.0%
C:
0.0%
MIRM
|
$24.0
-1.72%
-1.75%
320K
|
Health Technology
|
3.61%
|
O:
-0.68%
H:
2.52%
C:
1.71%
report
million
reach
treatment
market
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published:
2024-02-12
(Crawled : 14:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-6.29%
|
O:
0.07%
H:
0.46%
C:
0.42%
fda
first
treatment
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published:
2023-12-21
(Crawled : 00:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-2.52%
|
O:
2.05%
H:
0.29%
C:
0.0%
livtencity
approval
cytomegalovirus
treatment
china
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA Treatment for Rare form of Emphysema
Published:
2023-12-20
(Crawled : 14:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-3.16%
|
O:
0.36%
H:
0.14%
C:
-1.01%
rare
services
glassia
contract
treatment
blood
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published:
2023-11-21
(Crawled : 18:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-4.75%
|
O:
0.07%
H:
0.57%
C:
0.0%
cancer
treatment
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published:
2023-11-01
(Crawled : 18:00)
- prnewswire.com
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-21.94%
|
O:
-1.46%
H:
3.67%
C:
3.26%
ZYME
|
$8.555
-0.06%
-0.06%
590K
|
Health Technology
|
21.94%
|
O:
1.14%
H:
0.42%
C:
-0.7%
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-2.23%
|
O:
1.03%
H:
0.73%
C:
0.58%
ADCT
|
$4.78
-3.82%
0.0%
280K
|
Health Technology
|
640.58%
|
O:
-0.16%
H:
6.42%
C:
4.49%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
19.0%
|
O:
-0.86%
H:
0.0%
C:
0.0%
STRO
|
$3.47
-6.72%
-7.2%
540K
|
Health Technology
|
44.19%
|
O:
0.39%
H:
3.86%
C:
3.86%
IMGN
|
News
|
$31.23
0.03%
49M
|
Health Technology
|
109.1%
|
O:
5.09%
H:
5.48%
C:
-1.27%
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-16.41%
|
O:
-0.47%
H:
1.88%
C:
1.78%
EXEL
|
$23.7
1.76%
1.73%
1.5M
|
Health Technology
|
10.8%
|
O:
-2.62%
H:
1.17%
C:
-1.66%
drug
antibody
breast
cancer
treatment
global
market
Global Gastroparesis Treatment Market is Expected to Grow Revenue up to USD 11.09 Billion By 2030 with a Growing CAGR of 3.3% | Infinium Global Research
Published:
2023-10-27
(Crawled : 10:00)
- prnewswire.com
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-0.26%
|
O:
0.6%
H:
0.74%
C:
0.07%
PCSA
|
$1.67
4.38%
4.19%
40K
|
Producer Manufacturing
|
-75.2%
|
O:
-1.15%
H:
5.05%
C:
2.7%
expected
treatment
research
global
growing
market
Global Bleeding Disorders Treatment Market Surpasses $14 Billion in 2022, Expected to Reach $20.3 Billion by 2028
Published:
2023-10-25
(Crawled : 22:00)
- prnewswire.com
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-7.97%
|
O:
-4.69%
H:
0.69%
C:
-3.18%
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
32.03%
|
O:
-1.47%
H:
0.22%
C:
-0.83%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-1.26%
|
O:
0.1%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-11.36%
|
O:
0.09%
H:
0.0%
C:
0.0%
bleeding
expected
reach
disorders
treatment
global
market
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published:
2023-10-18
(Crawled : 22:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-10.5%
|
O:
-1.61%
H:
0.14%
C:
-0.27%
cd30
adcetris
treatment
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
Published:
2023-09-20
(Crawled : 14:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-18.13%
|
O:
0.12%
H:
0.43%
C:
-0.18%
tak-721
fda
resubmission
treatment
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
Published:
2023-09-11
(Crawled : 12:00)
- biospace.com/
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-12.26%
|
O:
1.31%
H:
0.91%
C:
0.52%
tak-279
active
positive
treatment
topline
results
study
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Published:
2023-07-20
(Crawled : 00:00)
- globenewswire.com
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-13.57%
|
O:
-0.65%
H:
0.49%
C:
0.07%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
62.94%
|
O:
0.35%
H:
2.21%
C:
1.9%
HCM
|
$18.405
0.85%
0.84%
58K
|
Health Technology
|
49.59%
|
O:
-0.33%
H:
2.55%
C:
1.4%
treatment
designation
china
therapy
study
Global Constipation Treatment Markets to 2030: A $27.5 Billion Industry Opportunity with Laxatives Accounting for $12.3 Billion
Published:
2023-06-19
(Crawled : 17:00)
- prnewswire.com
MNKPF
|
$17.25
|
n/a
|
Email alert
Add to watchlist
BHC
|
$8.56
0.35%
0.0%
2M
|
Health Technology
|
Email alert
Add to watchlist
MNKKQ
|
$0.02
|
Manufacturing
|
Email alert
Add to watchlist
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
Email alert
Add to watchlist
ALBO
|
$44.15
-0.23%
0.39%
1.2M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
Email alert
Add to watchlist
MNK
|
$0.3402
-0.06%
540K
|
n/a
|
Email alert
Add to watchlist
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
treatment
global
Global Addiction Treatment Market Report 2023: Sector to Reach $11.7 Billion by 2031 at a 6.1% CAGR
Published:
2023-05-26
(Crawled : 00:20)
- prnewswire.com
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
|
Email alert
Add to watchlist
SYK
|
$336.85
0.58%
0.0%
1.5M
|
Health Technology
|
Email alert
Add to watchlist
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
Email alert
Add to watchlist
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
Email alert
Add to watchlist
report
reach
treatment
global
market
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Published:
2023-05-25
(Crawled : 23:00)
- globenewswire.com
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-17.73%
|
O:
-0.62%
H:
0.62%
C:
-0.12%
HCM
|
$18.405
0.85%
0.84%
58K
|
Health Technology
|
49.47%
|
O:
7.45%
H:
3.66%
C:
2.06%
drug
review
treatment
application
Global Gaucher's Disease Treatment Market Research Report 2023: Emerging Therapies, Clinical Trials, Treatments, Current Scenario Evaluation, Patient Profile
Published:
2023-05-10
(Crawled : 18:00)
- prnewswire.com
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
|
11.63%
|
O:
0.92%
H:
0.0%
C:
0.0%
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-21.41%
|
O:
-1.83%
H:
0.12%
C:
-3.06%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
-4.6%
|
O:
-0.4%
H:
0.34%
C:
0.19%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-7.42%
|
O:
0.11%
H:
0.22%
C:
-0.52%
ABT
|
News
|
$106.89
-0.65%
-0.22%
5.1M
|
Health Technology
|
-2.8%
|
O:
-0.57%
H:
0.37%
C:
-0.01%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-13.01%
|
O:
-0.28%
H:
0.0%
C:
0.0%
disease
report
treatment
research
global
market
Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report 2023: New Drug Launches and Growing Awareness Fuels $32 Billion Industry
Published:
2023-04-27
(Crawled : 00:00)
- prnewswire.com
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
10.4%
|
O:
0.23%
H:
0.0%
C:
0.0%
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-20.85%
|
O:
-1.13%
H:
0.3%
C:
-0.48%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
-3.69%
|
O:
-0.79%
H:
0.89%
C:
0.72%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-8.18%
|
O:
-0.12%
H:
0.58%
C:
0.55%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
14.52%
|
O:
-0.25%
H:
0.97%
C:
0.31%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
89.33%
|
O:
1.96%
H:
1.59%
C:
-0.54%
drug
report
treatment
global
growing
market
Global Depression Treatment Market to 2030: Rising Prevalence of Psychiatric Diseases and Development of Innovative Medications for Treatment-resistant Depression Drives Growth
Published:
2023-04-04
(Crawled : 02:00)
- prnewswire.com
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-19.22%
|
O:
-0.12%
H:
1.55%
C:
1.03%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
110.71%
|
O:
0.38%
H:
1.97%
C:
0.72%
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-29.7%
|
O:
0.13%
H:
0.0%
C:
-1.25%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-13.51%
|
O:
-0.1%
H:
0.0%
C:
0.0%
depression
treatment
global
growth
market
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Published:
2023-03-31
(Crawled : 01:00)
- globenewswire.com
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-18.38%
|
O:
0.0%
H:
0.92%
C:
0.8%
HCM
|
$18.405
0.85%
0.84%
58K
|
Health Technology
|
36.19%
|
O:
-1.19%
H:
2.04%
C:
-1.66%
fda
cancer
treatment
submission
← Previous
1
2
3
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.